AR088474A1 - Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa - Google Patents

Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa

Info

Publication number
AR088474A1
AR088474A1 ARP120103932A ARP120103932A AR088474A1 AR 088474 A1 AR088474 A1 AR 088474A1 AR P120103932 A ARP120103932 A AR P120103932A AR P120103932 A ARP120103932 A AR P120103932A AR 088474 A1 AR088474 A1 AR 088474A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
optionally substituted
same
different
Prior art date
Application number
ARP120103932A
Other languages
English (en)
Inventor
Amari Gabriele
Capaldi Carmelida
Carzaniga Laura
La Porta Elena
Guala Matilde
Armani Elisabetta
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR088474A1 publication Critical patent/AR088474A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se relaciona con inhibidores de la enzima fosfodiesterasa 4 (PDE4). Más particularmente, la presente se relaciona con compuestos que son derivados de alcoholes de 1-fenil-2-piridinilalquilo, métodos para preparar dichos compuestos, composiciones que los contienen y el uso terapéutico de los mismos. Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1) donde: R¹ y R², que pueden ser iguales o diferentes, se seleccionan en forma independiente entre el grupo que consiste en: alquilo C₁₋₆, opcionalmente sustituido con cicloalquilo C₃₋₇; haloalquilo C₁₋₆; cicloalquilo C₃₋₇; y heterocicloalquilo C₃₋₇; R³ es hidrógeno, alquilo C₁₋₆ o alquiltio C₁₋₃-alquilo C₁₋₆; A es un sistema de anillos bicíclico parcialmente insaturado o insaturado que consiste en dos sistemas de anillos monocíclicos fusionados B y C como se representa en la fórmula (2), donde el anillo B contiene un átomo de nitrógeno que representa el punto de unión del anillo A al resto de la molécula a través de un grupo -(CHR³)- y donde los anillos B y C opcionalmente pueden contener otros heteroátomos; p es un entero entre cero y 3; Y es un grupo oxo; n es un entero entre cero y 3; K se selecciona entre el grupo que consiste en: alquilo C₁₋₆, opcionalmente sustituido con uno o más grupos cicloalquilo C₃₋₇; heterocicloalquil C₃₋₇-alquilo C₁₋₄; heterocicloalquilo C₃₋₇, opcionalmente sustituido con uno o más grupos alquilo C₁₋₆; haloalquilo C₁₋₄; un grupo -OR⁴ donde R⁴ se selecciona entre el grupo que consiste en: H; alquilo C₁₋₁₀, opcionalmente sustituido con cicloalquilo C₃₋₇ o heteroarilo; átomos de halógeno; un grupo -CN; un grupo -NO₂; NR⁵R⁶ donde R⁵ y R⁶, que pueden ser iguales o diferentes, se seleccionan en forma independiente entre el grupo que consiste en: H; un grupo -OH; alquil C₁₋₄-NR⁷R⁸ donde R⁷ y R⁸, que pueden ser iguales o diferentes, se seleccionan en forma independiente entre el grupo que consiste en: H; alquilo C₁₋₆, opcionalmente sustituido con alcoxilo C₁₋₆; y alquil C₁₋₆-NR⁹R¹⁰ donde R⁹ y R¹⁰, que pueden ser iguales o diferentes, son H o alquilo C₁₋₆; o forman con el átomo de nitrógeno al cual están unidos un anillo heterocicloalquilo C₃₋₇ opcionalmente sustituido con alquilo C₁₋₆ o un grupo alquil C₁₋₆carbonilo; alquilo C₁₋₆, opcionalmente sustituido con alcoxilo C₁₋₆ o heteroarilo, heterocicloalquilcarbonilo C₃₋₇, heteroarilcarbonilo, donde todos están opcionalmente sustituidos adicionalmente con uno o más grupos alquilo C₁₋₆, haloalquilo C₁₋₆ o alcoxilo C₁₋₆, que pueden ser iguales o diferentes y se seleccionan en forma independiente; un grupo -SO₂R¹¹, donde R¹¹ es alquilo C₁₋₆; un grupo -C(O)R¹², donde R¹² es alquilo C₁₋₆ opcionalmente sustituido con alcoxilo C₁₋₆; alquil C₁₋₄-NR¹³R¹⁴ donde R¹³ y R¹⁴, que pueden ser iguales o diferentes, se seleccionan en forma independiente en el grupo que consiste en: -SO₂-alquilo C₁₋₆, H, alquilo C₁₋₆, y heterocicloalquil C₃₋₇-alquilo C₁₋₄; y SO₂-NR¹⁵R¹⁶; donde R¹⁵ y R¹⁶, que pueden ser iguales o diferentes, son en forma independiente H o alquilo C₁₋₆; donde los grupos R⁴ a R¹⁶ pueden tener significados iguales o diferentes en cada caso, si se encuentran presentes en más de un grupo; o N-óxidos de piridina, sales farmacéuticamente aceptables, o solvatos de los mismos; y donde el compuesto de fórmula (1) no es: 3,5-dicloro-4-(2-(3-(ciclopropilmetoxi)-4-(difluorometoxi)fenil)-2-(2-(1,3-dimetil-2,6-dioxo-2,3-dihidro-1H-purin-7(6H)-il)acetoxi)etil)piridina.
ARP120103932A 2011-10-21 2012-10-19 Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa AR088474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11186056 2011-10-21

Publications (1)

Publication Number Publication Date
AR088474A1 true AR088474A1 (es) 2014-06-11

Family

ID=47080475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103932A AR088474A1 (es) 2011-10-21 2012-10-19 Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa

Country Status (10)

Country Link
US (1) US9024027B2 (es)
EP (1) EP2768822B1 (es)
KR (1) KR20140078719A (es)
CN (1) CN103889972A (es)
AR (1) AR088474A1 (es)
BR (1) BR112014009471A2 (es)
CA (1) CA2852723A1 (es)
HK (1) HK1198251A1 (es)
RU (1) RU2617401C2 (es)
WO (1) WO2013057013A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP2718267B1 (en) * 2011-06-06 2016-08-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR20150022789A (ko) 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
CA2932486A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
KR20160086351A (ko) * 2013-12-05 2016-07-19 키에시 파르마슈티시 엣스. 피. 에이. 호흡기 질환의 치료를 위한 헤테로아릴 유도체
EP3087069B1 (en) * 2013-12-23 2019-01-30 Norgine B.V. Compounds useful as ccr9 modulators
AR104829A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivados de aminoésteres
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
CN105061404B (zh) * 2015-07-21 2017-07-11 广东炜林纳新材料科技股份有限公司 一种亚酰胺类聚丙烯β晶型成核剂及其制备方法
CN106084465B (zh) * 2016-06-30 2019-03-01 广东炜林纳新材料科技股份有限公司 一种稀土类聚丙烯增刚成核剂及其制备方法
CN115466169B (zh) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 取代邻苯二酚醚类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9304571A (es) 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.
CA2165192C (en) * 1993-07-02 2001-04-24 Hermann Amschler Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
IT1276710B1 (it) 1995-06-14 1997-11-03 Zambon Spa Derivati dell'acido fosfinico ad attivita' inibitrice delle metallopeptidasi
EP1634606A1 (en) 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
EP2044023B1 (en) * 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
RU2014115290A (ru) 2015-11-27
US20130102576A1 (en) 2013-04-25
WO2013057013A3 (en) 2013-06-20
US9024027B2 (en) 2015-05-05
KR20140078719A (ko) 2014-06-25
HK1198251A1 (en) 2015-03-20
RU2617401C2 (ru) 2017-04-25
CN103889972A (zh) 2014-06-25
EP2768822B1 (en) 2017-12-06
WO2013057013A2 (en) 2013-04-25
EP2768822A2 (en) 2014-08-27
CA2852723A1 (en) 2013-04-25
BR112014009471A2 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
AR088474A1 (es) Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa
AR087841A1 (es) Derivados de tetrahidrotriazolopirimidina
PE20171240A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR123089A2 (es) Compuesto de piridinona
AR095706A1 (es) Indazoles sustituidos con heteroarilo
RU2014151850A (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR088760A1 (es) Derivados de pirrolopirimidina y purina
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR092742A1 (es) Piridinonas antifibroticas
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR093797A1 (es) Derivados de feniletilpiridina inhibidores de pde-4
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR093795A1 (es) Oxidos de piridinio, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades respiratorias
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR087563A1 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Legal Events

Date Code Title Description
FB Suspension of granting procedure